Last reviewed · How we verify
NCT03249818
HITT Device Pilot Testing for Traumatic Brain Injury
NA trial testing HITT device in Brain Injuries, Traumatic in 7 participants. Completed in 28 February 2018.
28 February 2018
Quick facts
| Lead sponsor | Rebiscan, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 7 |
| Start date | 22 August 2017 |
| Primary completion | 28 February 2018 |
| Estimated completion | 28 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HITT device
Conditions studied
- Brain Injuries, Traumatic — all drugs for Brain Injuries, Traumatic →
Sponsor
Rebiscan, Inc.
Who can join
Adults 18 to 40, any sex, with Brain Injuries, Traumatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to collect data from the eyes of traumatic brain injury (TBI) patients. Patients will look at a green target that will measure the fixation of the eye for 30 seconds. In that 30 seconds, the location of the green target will change and the participant is to track, with their eyes, the light as best they can. The device will measure how well fixation was maintained and the speed of the saccadic movements of the eye. Data will then be used to determine whether there is correlation between these measures and known TBI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03249818
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HITT device
Trials testing the same drug.
- NCT03653936 — Neuro-ocular Baselines in a Sports Setting · completed
Other recruiting trials for Brain Injuries, Traumatic
Currently open trials in the same condition.
- NCT06898242 — Early Myofascial Manual Treatment in Subjects With Spasticity Following Acquired Brain Injury · NA · active not recruiting
- NCT06413173 — Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric) · NA · recruiting
- NCT06142435 — mTBI Identification and Monitoring Through Retinal Scanning · recruiting
- NCT05117619 — The HOME Program for Individuals With Traumatic Brain Injury and Family Members · NA · recruiting
- NCT05092295 — Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury · active not recruiting
Other Rebiscan, Inc. trials
Trials by the same sponsor.
- NCT06142435 — mTBI Identification and Monitoring Through Retinal Scanning · recruiting
- NCT05092295 — Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury · active not recruiting
- NCT05092282 — HITT for the Identification of Mild Traumatic Brain Injury · active not recruiting
- NCT03919708 — Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging · withdrawn
- NCT03653936 — Neuro-ocular Baselines in a Sports Setting · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03249818 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rebiscan, Inc.
- Last refreshed: 29 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03249818.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing